Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01119118 | ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer | terminated | Phase 2 | 6 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT01533753 | Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02758132 | Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases | terminated | Phase 2 | 1 | University of HawaiiOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01562522 | Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.(EXPEDIENT) | terminated | Phase 2 | 6 | IpsenINDUSTRY | 1 | Nov 7, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT01253642 | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel | terminated | Phase 2 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01374087 | Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer(ANABRAQ) | terminated | Phase 2 | 32 | IpsenINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02710422 | Miami Membrane for Potency (MMEP) Trial(MMEP) | terminated | Phase 2 | 24 | University of MiamiOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01126879 | Genistein in Treating Patients With Prostate Cancer | terminated | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT02811159 | An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids | terminated | Phase 2 | 20 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02558348 | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)(AL3818) | terminated | Phase 1 / Phase 2 | 12 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01958112 | GSK1120212+GSK2141795 for Cervical Cancer | terminated | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | terminated | Phase 1 / Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 17, 2019 | clinicaltrials |
| NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer(SEASCAPE) | terminated | Phase 1 / Phase 2 | 35 | Aduro Biotech, Inc.INDUSTRY | 2 | Apr 4, 2019 | clinicaltrials |
| NCT00996502 | Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01994590 | Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01685255 | A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | terminated | Phase 2 | 83 | Incyte CorporationINDUSTRY | 6 | Mar 11, 2019 | clinicaltrials |
| NCT01163084 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2019 | clinicaltrials |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | terminated | Phase 1 / Phase 2 | 1 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02459912 | Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer(POTENT-C) | terminated | Phase 2 | 1 | NYU Langone HealthOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT01251354 | Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy | terminated | Phase 2 | 6 | IpsenINDUSTRY | 2 | Jan 14, 2019 | clinicaltrials |
| NCT00924807 | Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Medical CenterOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00526591 | Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer | terminated | Phase 2 | 17 | Jorge A. Garcia, MDOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT01703065 | Cabozantinib in Men With Castration-Resistant Prostate Cancer | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT02494713 | Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | terminated | Phase 2 | 4 | The University of Texas Health Science Center, HoustonOTHER | 1 | Nov 27, 2018 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00103376 | Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer | terminated | Phase 2 | 23 | Medical University of South CarolinaOTHER | 1 | Nov 5, 2018 | clinicaltrials |
| NCT02868892 | A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas | terminated | Phase 2 | 6 | Western Regional Medical CenterOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00080782 | Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases | terminated | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01354951 | Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer | terminated | Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2018 | clinicaltrials |
| NCT00670046 | Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer | terminated | Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT00322881 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer(KHLAD) | terminated | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT00527124 | Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01439542 | FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer(FASTR) | terminated | Phase 2 | 19 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01335204 | Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Medical University of South CarolinaOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT00634582 | Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Jul 6, 2018 | clinicaltrials |
| NCT00058448 | S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 28, 2018 | clinicaltrials |
| NCT02215161 | Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 2 | 14 | University of California, San FranciscoOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT01845792 | Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer | terminated | Phase 2 | 7 | University of Colorado, DenverOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT00866723 | Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer | terminated | Phase 2 | 5 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 22, 2018 | clinicaltrials |
| NCT00005029 | Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 12, 2018 | clinicaltrials |
| NCT01773889 | A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer | terminated | Phase 2 | 2 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT00860158 | Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer | terminated | Phase 2 | 1 | Noah Hahn, M.D.OTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT00408070 | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 2 | 5 | UConn HealthOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT01936974 | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma(PGA) | terminated | Phase 2 | 7 | Western Regional Medical CenterOTHER | 1 | Feb 20, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Nov 21, 2019source: clinicaltrials